Information
ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading ...
Original sourceAI Summary
Milestone Scientific has introduced the CompuFlo® Advisor Program, aimed at increasing market adoption and establishing better Medicare reimbursement for their products. By engaging Key Opinion Leaders and targeting high-volume practices, they plan to gather critical clinical data to transition CPT® code 0777T to Category I status, potentially driving significant revenue growth.
Sentiment Rationale
Milestone's strategic alignment with reimbursement enhancement can drive future revenue, similar to past successful medical device transitions that improved profitability and market adoption.
Trading Thesis
Given the potential for enhanced reimbursement and revenue visibility, MLSS is a strong buy for the next 6-12 months.
Market-Moving
- Successful transition to Category I status could significantly boost revenues.
- Engagement of KOLs may drive higher adoption rates in targeted practices.
- The initial 1,000–2,000 case submissions will provide critical validation.
- Medicare reimbursement rates improvements could enhance recurring revenue streams.
Key Facts
- Milestone launched the CompuFlo® Advisor Program for commercial adoption.
- The program targets high-volume pain and anesthesia practices nationwide.
- Milestone aims for Category I status for CPT® code 0777T to boost revenue.
- The initiative will generate clinical data for better Medicare reimbursement.
- Engaging KOLs, Milestone aims for 1,000–2,000 case submissions within six months.
Companies Mentioned
- Medicare Administrative Contractors (MAC): Targeted for enhanced reimbursement through the new program.
- Neuro Management Solutions (NMS): Provides claims support and could streamline reimbursement processes.
Corporate Developments
This initiative fits under 'Corporate Developments' as it represents a strategic move by Milestone Scientific to enhance its market positioning and revenue streams while navigating regulatory frameworks for reimbursement improvements.